Kudos to Times reporter Pam Belluck for writing responsibly about lecanemab:

"That history gives the lecanemab trial added significance, marking the first time that attacking amyloid has clearly correlated with a slower rate of cognitive decline, experts say. But because the rate was not dramatically slower, several doctors who treat Alzheimer’s questioned whether the effect would be noticeable to patients or their families."

https://www.nytimes.com/2022/11/29/health/lecanemab-alzheimers-drug.html